🔹Orchard Therapeutics is a world leader in the development of gene therapies for the treatment of severe diseases. Orchard’s approach utilizes a patients own hematopoietic stem cells (HSCs) to deliver therapeutic genes to target organs and tissues. As Orchard investigates future therapies, it is naturally keen to explore new technologies like Cellular Highways VACS™.

In Orchard’s lab the team conducted a direct comparison between Highway1 and a leading conventional sorter and…

➡️Cytometry was equivalent
➡️Output purity and yield were similar between the two.

🔹However, Highway1 outperformed by running more than 2x faster and sterile sorting was a breeze, while the conventional sorter struggled.

🔹Following the sorting process, a 14-day functional evaluation of the cells was conducted. The good news is that the cells maintained high viability and purity, indicating no adverse effects from the sorting process!

Thanks to the Orchard Therapeutics team for testing Highway1 with us. We’re thrilled to see our system making such a positive impact.